Spots Global Cancer Trial Database for A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients

Official Title: A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients

Study ID: NCT01506427

Conditions

Head and Neck Cancer

Interventions

[F-18] HX4

Study Description

Brief Summary: The purpose of this trial is to determine what will be the optimal imaging protocol for Head and Neck Cancer patients after \[F-18\] HX4 injection. This study will provide guidance for future studies involving \[F-18\]HX4 in cancer patients.

Detailed Description: Each consented patient will have a single administration of \[F-18\]HX4 and will immediately undergo one list mode PET/CT imaging session lasting 60 minutes followed by three additional list mode PET/CT acquisitions from 90 to 110 minutes, 150 to 170 minutes and 220 to 250 minutes after administration. The start times of the last three image acquisitions are permitted to be within ± 5 minutes. Venous blood samples will be collected throughout the initial scan sequence and at the time of each subsequent acquisition for calibration and metabolite-correction of the image-derived input function. On the day of administration (Visit 2) blood for clinical safety evaluations will be drawn pre- and post-dosing after all imaging is complete. The pre-surgery \[F-18\]FDG PET/CT clinical scan performed prior to the \[F-18\]HX4 procedure, and the surgery at Visit 3 are standard of care for the consented patients.